GRAPHIC OMITTED][GRAPHIC OMITTED]
INVESTORS CONTACT: MEDIA CONTACT:
Susan Mesco Kim Angelastro
Cytogen Corporation Berry & Co. Public Relations
(609) 750-8213 (212)253-8881
CYTOGEN ACQUIRES NORTH AMERICAN MARKETING RIGHTS TO CAPHOSOL(R)
FOR TREATMENT OF BOTH ORAL MUCOSITIS AND DRY MOUTH
PRESCRIPTION PRODUCT EXPANDS CYTOGEN'S PORTFOLIO OF SUPPORTIVE
CARE PRODUCTS IN ONCOLOGY WITH ORAL AGENT TO TREAT
CERTAIN COMMON SIDE EFFECTS OF CHEMOTHERAPY AND
RADIATION.
PRINCETON, N.J., (OCTOBER 11, 2006) -- Cytogen Corporation (NASDAQ: CYTO) today
announced it has licensed the exclusive North American rights to CAPHOSOL(R)
from InPharma AS (Norway, private). CAPHOSOL, a topical oral agent, is a
prescription medical device indicated in the U.S. as an adjunct to standard oral
care in treating oral mucositis caused by radiation or high dose chemotherapy, a
condition estimated to affect more than 400,000 cancer patients each year.
CAPHOSOL is also indicated for dryness of the mouth (hyposalivation) or dryness
of the throat (xerostomia) regardless of the cause or whether the conditions are
temporary or permanent.
"With the addition of CAPHOSOL, Cytogen will have four marketed oncology
products. Our focused experience in sales and marketing in oncology leaves us
well positioned to maximize the commercial potential of CAPHOSOL while creating
even stronger marketing synergies within our oncology portfolio," said Michael
Becker, president and chief executive officer.
Under the terms of the agreement, InPharma will receive upfront fees of $5
million upon the closing of the transaction and an additional $1 million payment
after six months. In addition, InPharma will receive royalties and sales-based
milestone payments. The transaction also provides Cytogen with the option to
acquire the rights to CAPHOSOL for the European and Asian markets.
Oral mucositis is an inflammation of mucous membranes in the mouth with symptoms
ranging from redness to severe ulcerations. Approximately 40% of patients who
receive chemotherapy develop some form of oral mucositis during the course of
their treatment. In addition, more than 70% of patients undergoing conditioning
therapy for bone marrow transplantation and virtually all patients receiving
radiation therapy to the head and neck areas develop oral mucositis. Both
chemotherapy and radiation can also cause dryness of the mouth (hyposalivation)
or throat (xerostomia), with an estimated 40% of patients undergoing
chemotherapy reporting this side effect.
"Minimizing the common and painful oral complications associated with cancer
treatment is a critical goal in patient care that represents a significant
commercial opportunity. With our experience in the medical and radiation
oncology markets, we believe Cytogen will be able to maximize the value
potential of this device while bringing this treatment option to even more
patients affected by oral mucositis," Mr. Becker added.
Cytogen expects to introduce CAPHOSOL in the U.S. market in early 2007.
About CAPHOSOL
- --------------
CAPHOSOL, a topical oral agent, is a U.S. patented, prescription medical device
that lubricates the mucosa and helps maintain the integrity of the oral cavity
through its mineralizing potential. The distinguishing feature of CAPHOSOL is
its high concentrations of calcium and phosphate ions, which are hypothesized to
exert their beneficial effects by diffusing into intracellular spaces in the
epithelium and permeating the mucosal lesion in mucositis. Calcium ions play a
crucial role in several aspects of the inflammatory process, the blood clotting
cascade, and tissue repair and phosphate ions may be a valuable supplemental
source of phosphates for damaged mucosal surfaces.
A prospective, randomized, double-blind, placebo-controlled trial demonstrated
CAPHOSOL to be a significant adjunct in the management of mucositis associated
with high-dose chemotherapy and radiation therapy. The trial evaluated 95
patients undergoing hematopoietic stem cell transplantation with the duration
and severity of mucositis and requirements for opioid medications prospectively
evaluated. Data demonstrated significant decreases in days of mucositis (3.72
vs. 7.20, P=0.001), duration of pain (2.86 vs. 7.67, P=0.0001), dose of morphine
(30.46 mg vs. 127.96 mg), and days of morphine (1.26 vs. 4.02, P=0.0001) for
patients receiving CAPHOSOL as compared to those administered a placebo. The
lead investigator for the study was Athena Papas, DMD, PhD, Department of Oral
Medicine, Tufts University School of Medicine, Boston MA and results were
published in the April 2003 issue of Bone Marrow Transplant (Papas et al. Bone
Marrow Transplant. 2003 April:31(8):705-12).
CAPHOSOL Indications:
- --------------------
CAPHOSOL is indicated in the U.S. as an adjunct to standard oral care in
treating oral mucositis caused by radiation or high dose chemotherapy. Relief of
dryness of the oral mucosa in these conditions is associated with an
amelioration of pain. CAPHOSOL is also indicated for dryness of the mouth
(hyposalivation) or throat (xerostomia) regardless of the cause or whether the
conditions are temporary or permanent. CAPHOSOL is an unclassified medical
device and is marketed under a 510(k) Premarket Notification Application.
About Oral Complications of Cancer Therapy
- ------------------------------------------
Oral complications including mucositis and salivary gland dysfunction are common
and often debilitating side effects of cancer therapy. Patients affected by oral
complications
may be unable to tolerate different forms of therapy, potentially resulting in
missed doses, dose reductions or the discontinuation of treatment. Preventing
and controlling oral complications can enhance a patient's quality of life, as
well as the effectiveness of cancer therapy.
About Cytogen
- -------------
Founded in 1980, Cytogen is a biopharmaceutical company dedicated to advancing
the care of cancer patients by acquiring, developing, and commercializing
innovative pharmaceutical products. The Company's specialty sales force
currently markets QUADRAMET(R), PROSTASCINT(R), and SOLTAMOX(TM) to the U.S.
oncology market. QUADRAMET is approved for the treatment of pain in patients
whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal
antibody-based agent to image the extent and spread of prostate cancer, and
SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the
treatment of breast cancer in adjuvant and metastatic settings. The Company is
also developing CYT-500, a third-generation radiolabeled antibody to treat
prostate cancer. Cytogen's product-focused strategy focuses on attaining
sustainable growth through clinical, commercial, and strategic initiatives.
THIS PRESS RELEASE CONTAINS CERTAIN "FORWARD-LOOKING" STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND SECTION 21E
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. ALL STATEMENTS, OTHER THAN
STATEMENTS OF HISTORICAL FACTS, INCLUDED IN THIS PRESS RELEASE REGARDING OUR
STRATEGY, FUTURE OPERATIONS, FINANCIAL POSITION, FUTURE REVENUES, PROJECTED
COSTS, PROSPECTS, PLANS AND OBJECTIVES OF MANAGEMENT ARE FORWARD-LOOKING
STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS INVOLVE A NUMBER OF RISKS AND
UNCERTAINTIES AND INVESTORS ARE CAUTIONED NOT TO PUT ANY UNDUE RELIANCE ON ANY
FORWARD-LOOKING STATEMENT. THERE ARE A NUMBER OF IMPORTANT FACTORS THAT COULD
CAUSE CYTOGEN'S RESULTS TO DIFFER MATERIALLY FROM THOSE INDICATED BY SUCH
FORWARD-LOOKING STATEMENTS. IN PARTICULAR, CYTOGEN'S BUSINESS IS SUBJECT TO A
NUMBER OF SIGNIFICANT RISKS, WHICH INCLUDE, BUT ARE NOT LIMITED TO: THE RISK OF
SUCCESSFULLY MARKETING CAPHOSOL; THE RISK OF OBTAINING THE NECESSARY REGULATORY
APPROVALS; THE RISK OF WHETHER PRODUCTS RESULT FROM DEVELOPMENT ACTIVITIES; THE
RISK OF SHIFTS IN THE REGULATORY ENVIRONMENT AFFECTING SALES OF CYTOGEN'S
PRODUCTS SUCH AS THIRD-PARTY PAYOR REIMBURSEMENT ISSUES; THE RISK ASSOCIATED
WITH CYTOGEN'S DEPENDENCE ON ITS PARTNERS FOR DEVELOPMENT OF CERTAIN PROJECTS,
AS WELL AS OTHER FACTORS EXPRESSED FROM TIME TO TIME IN CYTOGEN'S PERIODIC
FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC"). AS A RESULT,
THIS PRESS RELEASE SHOULD BE READ IN CONJUNCTION WITH CYTOGEN'S PERIODIC FILINGS
WITH THE SEC. THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE MADE ONLY AS
OF THE DATE OF THIS PRESS RELEASE, AND CYTOGEN UNDERTAKES NO OBLIGATION TO
PUBLICLY UPDATE SUCH FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR
CIRCUMSTANCES
###